Replimune Group, Inc. (REPL)
Stock Price:
$44.14 USD
-0.75 (-1.67%)
Updated Oct 28, 2020 11:14 AM EDT - Market open
Key Info
| Market Cap |
1.78B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-60.61M |
| Shares Out |
40.29M |
| EPS (ttm) |
-1.67 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$44.14 |
| Previous Close |
$44.89 |
| Change ($) |
-0.75 |
| Change (%) |
-1.67% |
| Day's Open |
44.37 |
| Day's Range |
42.58 - 45.04 |
| Day's Volume |
51,732 |
| 52-Week Range |
8.58 - 47.96 |
More Stats
| Market Cap |
1.78B |
| Enterprise Value |
1.56B |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
40.29M |
| Float |
19.55M |
| EPS (basic) |
-1.66 |
| EPS (diluted) |
-1.67 |
| FCF / Share |
-1.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
933,529 |
| Short Ratio |
0.76 |
| Short % of Float |
4.78% |
| Beta |
3.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.55 |
| Revenue |
n/a |
| Operating Income |
-63.12M |
| Net Income |
-60.61M |
| Free Cash Flow |
-69.17M |
| Net Cash |
220.25M |
| Net Cash / Share |
5.47 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-15.85% |
| ROE |
-29.71% |
| ROIC |
-29.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$49.38*
(11.87% upside)
Low
44.0
Current: $44.14
High
54.0
Target: 49.38
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -56.20 | -30.95 | -19.23 | -9.65 |
| Net Income | -52.63 | -30.83 | -19.70 | -7.70 |
| Shares Outstanding | 34.26 | 23.20 | 4.98 | 4.97 |
| Earnings Per Share | -1.54 | -1.33 | -3.96 | -1.55 |
| Operating Cash Flow | -60.55 | -25.38 | -16.01 | -7.08 |
| Capital Expenditures | -6.54 | -2.60 | -0.14 | -0.24 |
| Free Cash Flow | -67.09 | -27.98 | -16.15 | -7.32 |
| Cash & Equivalents | 170 | 136 | 61.63 | 20.67 |
| Total Debt | 41.79 | 6.56 | - | - |
| Net Cash / Debt | 128 | 129 | 61.63 | 20.67 |
| Assets | 234 | 154 | 65.15 | 22.82 |
| Liabilities | 50.38 | 16.47 | 6.86 | 2.73 |
| Book Value | 184 | 138 | -28.07 | -11.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Replimune Group, Inc. |
| Country |
United States |
| Employees |
122 |
| CEO |
Philip Astley-Sparke |
Stock Information
| Ticker Symbol |
REPL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: REPL |
| IPO Date |
July 20, 2018 |
Description
Replimune Group, a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.